Institution
Yale University
Education•New Haven, Connecticut, United States•
About: Yale University is a education organization based out in New Haven, Connecticut, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 89824 authors who have published 220665 publications receiving 12834776 citations. The organization is also known as: Yale & Collegiate School.
Topics: Population, Poison control, Medicine, Cancer, Health care
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A molecule containing a nitroamine redox center was used in the active self-assembled monolayer in an electronic device that exhibited negative differential resistance and an on-off peak-to-valley ratio in excess of 1000:1.
Abstract: A molecule containing a nitroamine redox center (2'-amino-4-ethynylphenyl-4'-ethynylphenyl-5'-nitro-1-benzenethiol) was used in the active self-assembled monolayer in an electronic device. Current-voltage measurements of the device exhibited negative differential resistance and an on-off peak-to-valley ratio in excess of 1000:1.
2,295 citations
••
TL;DR: Single-cell recordings in monkeys, and neurophysiological and neuroimaging studies in humans, reveal that cerebral cortex in and near the superior temporal sulcus (STS) region is an important component of this perceptual system.
2,290 citations
••
Emory University1, University of Iowa2, Wayne State University3, Brown University4, Case Western Reserve University5, University of Cincinnati6, University of Alabama at Birmingham7, University of Texas Health Science Center at Houston8, Indiana University9, University of California, San Diego10, Yale University11, University of Miami12, University of Texas Southwestern Medical Center13, Wake Forest University14, Duke University15, Stanford University16, University of Utah17, University of Rochester18, Tufts University19, University of New Mexico20, National Institutes of Health21
TL;DR: Although the majority of infants with GAs of ≥24 weeks survive, high rates of morbidity among survivors continue to be observed.
Abstract: OBJECTIVE: This report presents data from the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network on care of and morbidity and mortality rates for very low birth weight infants, according to gestational age (GA). METHODS: Perinatal/neonatal data were collected for 9575 infants of extremely low GA (22–28 weeks) and very low birth weight (401–1500 g) who were born at network centers between January 1, 2003, and December 31, 2007. RESULTS: Rates of survival to discharge increased with increasing GA (6% at 22 weeks and 92% at 28 weeks); 1060 infants died at ≤12 hours, with most early deaths occurring at 22 and 23 weeks (85% and 43%, respectively). Rates of prenatal steroid use (13% and 53%, respectively), cesarean section (7% and 24%, respectively), and delivery room intubation (19% and 68%, respectively) increased markedly between 22 and 23 weeks. Infants at the lowest GAs were at greatest risk for morbidities. Overall, 93% had respiratory distress syndrome, 46% patent ductus arteriosus, 16% severe intraventricular hemorrhage, 11% necrotizing enterocolitis, and 36% late-onset sepsis. The new severity-based definition of bronchopulmonary dysplasia classified more infants as having bronchopulmonary dysplasia than did the traditional definition of supplemental oxygen use at 36 weeks (68%, compared with 42%). More than one-half of infants with extremely low GAs had undetermined retinopathy status at the time of discharge. Center differences in management and outcomes were identified. CONCLUSION: Although the majority of infants with GAs of ≥24 weeks survive, high rates of morbidity among survivors continue to be observed.
2,277 citations
••
TL;DR: The results indicate that any degree of albuminuria is a risk factor for CV events in individuals with or without DM; the risk increases with the ACR, starting well below the microalbuminuria cutoff.
Abstract: ContextMicroalbuminuria is a risk factor for cardiovascular (CV) events. The
relationship between the degree of albuminuria and CV risk is unclear.ObjectivesTo estimate the risk of CV events in high-risk individuals with diabetes
mellitus (DM) and without DM who have microalbuminuria and to determine whether
levels of albuminuria below the microalbuminuria threshold increase CV risk.DesignThe Heart Outcomes Prevention Evaluation study, a cohort study conducted
between 1994 and 1999 with a median 4.5 years of follow-up.SettingCommunity and academic practices in North and South America and Europe.ParticipantsIndividuals aged 55 years or more with a history of CV disease (n =
5545) or DM and at least 1 CV risk factor (n = 3498) and a baseline urine
albumin/creatinine ratio (ACR) measurement.Main Outcome MeasuresCardiovascular events (myocardial infarction, stroke, or CV death);
all-cause death; and hospitalization for congestive heart failure.ResultsMicroalbuminuria was detected in 1140 (32.6%) of those with DM and 823
(14.8%) of those without DM at baseline. Microalbuminuria increased the adjusted
relative risk (RR) of major CV events (RR, 1.83; 95% confidence interval [CI],
1.64-2.05), all-cause death (RR, 2.09; 95% CI, 1.84-2.38), and hospitalization
for congestive heart failure (RR, 3.23; 95% CI, 2.54-4.10). Similar RRs were
seen for participants with or without DM, even after adjusting for other CV
risk factors (eg, the adjusted RR of the primary aggregate end point was 1.97
[95% CI, 1.68-2.31] in those with DM and 1.61 [95% CI, 1.36-1.90] in those
without DM).Compared with the lowest quartile of ACR (<0.22 mg/mmol), the
RRs of the primary aggregate end point in the second quartile (ie, ACR range,
0.22-0.57 mg/mmol) was 1.11 (95% CI, 0.95-1.30); third quartile, 1.38 (95%
CI, 1.19-1.60; ACR range, 0.58-1.62 mg/mmol); and fourth quartile, 1.97 (95%
CI, 1.73-2.25; ACR range, >1.62 mg/mmol) (P for trend
<.001, even after excluding those with microalbuminuria). For every 0.4-mg/mmol
increase in ACR level, the adjusted hazard of major CV events increased by
5.9% (95% CI, 4.9%-7.0%).ConclusionsOur results indicate that any degree of albuminuria is a risk factor
for CV events in individuals with or without DM; the risk increases with the
ACR, starting well below the microalbuminuria cutoff. Screening for albuminuria
identifies people at high risk for CV events.
2,273 citations
••
Daniel J. Eisenstein1, Daniel J. Eisenstein2, David H. Weinberg3, Eric Agol4 +260 more•Institutions (62)
TL;DR: SDSS-III as mentioned in this paper is a program of four spectroscopic surveys on three scientific themes: dark energy and cosmological parameters, the history and structure of the Milky Way, and the population of giant planets around other stars.
Abstract: Building on the legacy of the Sloan Digital Sky Survey (SDSS-I and II), SDSS-III is a program of four spectroscopic surveys on three scientific themes: dark energy and cosmological parameters, the history and structure of the Milky Way, and the population of giant planets around other stars. In keeping with SDSS tradition, SDSS-III will provide regular public releases of all its data, beginning with SDSS DR8 (which occurred in Jan 2011). This paper presents an overview of the four SDSS-III surveys. BOSS will measure redshifts of 1.5 million massive galaxies and Lya forest spectra of 150,000 quasars, using the BAO feature of large scale structure to obtain percent-level determinations of the distance scale and Hubble expansion rate at z 100 per resolution element), H-band (1.51-1.70 micron) spectra of 10^5 evolved, late-type stars, measuring separate abundances for ~15 elements per star and creating the first high-precision spectroscopic survey of all Galactic stellar populations (bulge, bar, disks, halo) with a uniform set of stellar tracers and spectral diagnostics. MARVELS will monitor radial velocities of more than 8000 FGK stars with the sensitivity and cadence (10-40 m/s, ~24 visits per star) needed to detect giant planets with periods up to two years, providing an unprecedented data set for understanding the formation and dynamical evolution of giant planet systems. (Abridged)
2,265 citations
Authors
Showing all 91064 results
Name | H-index | Papers | Citations |
---|---|---|---|
Richard A. Flavell | 231 | 1328 | 205119 |
Eugene Braunwald | 230 | 1711 | 264576 |
Matthias Mann | 221 | 887 | 230213 |
Bruce S. McEwen | 215 | 1163 | 200638 |
Robert J. Lefkowitz | 214 | 860 | 147995 |
Edward Giovannucci | 206 | 1671 | 179875 |
Rakesh K. Jain | 200 | 1467 | 177727 |
Francis S. Collins | 196 | 743 | 250787 |
Lewis C. Cantley | 196 | 748 | 169037 |
Martin White | 196 | 2038 | 232387 |
Ronald Klein | 194 | 1305 | 149140 |
Thomas C. Südhof | 191 | 653 | 118007 |
Michael Rutter | 188 | 676 | 151592 |
David H. Weinberg | 183 | 700 | 171424 |
Douglas R. Green | 182 | 661 | 145944 |